查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1668176

非小細胞肺癌市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、按治療、按藥物類別、按最終用戶、按地區和競爭進行細分，2020-2030 年預測

Non-Small Cell Lung Cancer Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Treatment, By Drug Class, By End-User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球非小細胞肺癌市場價值為 198.1 億美元，預計到 2030 年將達到 361.3 億美元，複合年成長率為 10.51% 隨著治療方案的進步和對疾病潛在機制的更好理解，全球非小細胞肺癌 (NSCLC) 市場正在經歷顯著成長。非小細胞肺癌是最常見的肺癌類型，其診斷準確率已提高，可以更早發現並改善預後。隨著標靶治療和免疫療法等個人化治療方案的日益採用，NSCLC 管理的前景發生了巨大變化。液體活體組織切片和分子分析等先進診斷技術的出現有助於識別與癌症進展相關的基因突變和標記，從而實現更精準的治療針對性。這刺激了針對特定基因突變的治療方法的需求，例如 EGFR 和 ALK 抑制劑。此外，將傳統化療與免疫療法或標靶藥物結合的聯合療法已被證明可以顯著改善患者的治療效果。

市場概況
預測期 2026-2030
2024 年市場規模 198.1 億美元
2030 年市場規模 361.3 億美元
2025-2030 年複合年成長率 10.51％
成長最快的領域 醫院和診所
最大的市場 北美洲

全球醫療支出的增加和政府對癌症研究的資助增加進一步促進了市場的成長。免疫檢查點抑制劑等新型藥物的引入徹底改變了 NSCLC 患者的治療方法。像 pembrolizumab 和 nivolumab 這樣的藥物在提高生存率方面表現出了良好的前景，從而導致對這些療法的需求增加。正在進行的臨床試驗和治療方法的突破繼續推動市場的創新。此外，伴隨診斷的進步使醫療保健提供者能夠更有效地個人化治療，從而有助於新療法的成功。因此，製藥公司和生技公司正在大力投資 NSCLC 藥物開發，以滿足對更有效治療日益成長的需求。

儘管市場呈現出巨大的成長潛力，但挑戰依然存在，特別是在治療可負擔性和獲得先進療法方面。新型癌症治療方法，尤其是標靶療法和免疫療法成本高昂，往往會限制患者獲得治療，特別是在中低收入國家。此外，NSCLC治療方案的複雜性可能導致不良的副作用，從而引發對患者堅持長期治療的擔憂。藥品核准所涉及的監管障礙以及對更全面的臨床資料的需求也阻礙了新療法進入市場的速度。儘管存在這些挑戰，但仍有大量的成長機會，特別是隨著對 NSCLC 的研究不斷發現新的生物標記和治療方法。對早期檢測、以患者為中心的護理以及微創療法開發的日益關注，為未來幾年製藥和生物技術公司帶來了重大機會。

主要市場促進因素

診斷技術的進步

人口結構和生活方式選擇的變化

主要市場挑戰

治療抵抗

主要市場趨勢

精準醫療和標靶治療

分段洞察

類型洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第5章：全球非小細胞肺癌市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按類型（腺癌、鱗狀細胞癌、大細胞癌）
    • 依治療方法（化療、免疫治療、放射治療、手術、標靶治療藥物）
    • 依藥物類別（血管新生抑制劑、表皮生長因子受體阻斷劑、激酶抑制劑、微管穩定劑、葉酸抗代謝物、PD-1/PD-L1 抑制劑）
    • 按最終使用者（醫院和診所、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第 6 章：北美非小細胞肺癌市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 加拿大
    • 墨西哥

第 7 章：歐洲非小細胞肺癌市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太非小細胞肺癌市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲非小細胞肺癌市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲非小細胞肺癌市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 合併與收購

第 13 章：全球非小細胞肺癌市場：SWOT 分析

第 14 章：競爭格局

  • Bayar Healthcare AG
  • Eli Lilly & Co.
  • Biogen Inc
  • Merck $ Co
  • AbbVie Inc
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc
  • Avid Bioservices Inc
  • Blueprint Medicines Company

第 15 章：策略建議

第16章 關於出版商,免責事項

簡介目錄
Product Code: 17497

Global Non-Small Cell Lung Cancer Market was valued at USD 19.81 Billion in 2024 and is expected to reach USD 36.13 Billion in the forecast period with a CAGR of 10.51% through 2030. The global Non-Small Cell Lung Cancer (NSCLC) market is experiencing significant growth due to advancements in treatment options and a better understanding of the disease's underlying mechanisms. NSCLC, the most common form of lung cancer, has seen a rise in diagnostic accuracy, allowing for earlier detection and improved prognosis. With the increasing adoption of personalized treatment regimens, such as targeted therapies and immunotherapies, the landscape for NSCLC management has dramatically shifted. The emergence of advanced diagnostic technologies, including liquid biopsy and molecular profiling, has helped identify genetic mutations and markers associated with cancer progression, allowing for more accurate treatment targeting. This has fueled demand for therapies tailored to specific genetic mutations, such as EGFR and ALK inhibitors. Furthermore, combination therapies, which pair traditional chemotherapy with immunotherapies or targeted drugs, have shown to significantly improve patient outcomes.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 19.81 Billion
Market Size 2030USD 36.13 Billion
CAGR 2025-203010.51%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Rising healthcare expenditure globally and increased government funding for cancer research have further contributed to the market's growth. The introduction of new drug classes, such as immune checkpoint inhibitors, has revolutionized the treatment approach for NSCLC patients. Drugs like pembrolizumab and nivolumab have shown promise in increasing survival rates, leading to heightened demand for these therapies. Ongoing clinical trials and breakthroughs in treatment approaches continue to drive innovation in the market. Furthermore, advancements in companion diagnostics have enabled healthcare providers to personalize treatments more effectively, contributing to the success of new therapies. As a result, pharmaceutical companies and biotechnology firms are investing heavily in NSCLC drug development to meet the growing demand for more effective treatments.

While the market presents substantial growth potential, challenges persist, particularly in terms of treatment affordability and access to advanced therapies. The high cost of novel cancer treatments, especially targeted therapies and immunotherapies, often limits patient access, particularly in low- and middle-income countries. Moreover, the complexity of NSCLC treatment regimens can result in adverse side effects, leading to concerns about patient adherence to long-term therapies. The regulatory hurdles involved in drug approval and the need for more comprehensive clinical data are also impeding the speed at which new therapies reach the market. Despite these challenges, opportunities for growth are abundant, especially as research into NSCLC continues to uncover new biomarkers and treatment approaches. The increasing focus on early-stage detection, patient-centric care, and the development of less invasive therapies presents significant opportunities for pharmaceutical and biotechnology companies in the coming years.

Key Market Drivers

Advances in Diagnostic Technologies

Advances in diagnostic technologies are playing a crucial role in driving the growth of the global Non-Small Cell Lung Cancer (NSCLC) market. Early and accurate detection of NSCLC significantly impacts treatment outcomes and survival rates. Traditional diagnostic methods, such as X-rays and CT scans, are now complemented by more advanced technologies, including high-resolution imaging, molecular profiling, and next-generation sequencing (NGS). These innovations allow for more precise tumor characterization, enabling physicians to identify specific genetic mutations and alterations in NSCLC tumors, such as EGFR, ALK, and ROS1 mutations, which can be targeted by specific therapies. According to the American Cancer Society, lung cancer is the leading cause of cancer-related deaths in the United States, with an estimated 228,820 new cases and 135,720 deaths projected for 2020.

Liquid biopsy techniques have emerged as a significant breakthrough in NSCLC diagnostics. Liquid biopsies are non-invasive, requiring only blood samples to detect cancer-related biomarkers, including circulating tumor DNA (ctDNA) and exosomes. This method enables real-time monitoring of tumor progression, detection of resistance mutations, and evaluation of treatment efficacy. Liquid biopsy's ability to provide continuous, non-invasive updates on a patient's condition reduces the need for invasive tissue biopsies and provides valuable insights into the molecular dynamics of the tumor. A study published in the Journal of Clinical Oncology reported that integrating liquid biopsy into the clinical practice of patients with NSCLC increased actionable aberration detection rates by 42% when tissue NGS was not performed.

Immunohistochemistry (IHC) and molecular imaging techniques, such as positron emission tomography (PET), are improving the detection of early-stage tumors and providing accurate assessments of the tumor's location and size. These advanced diagnostic tools are helping to stratify patients based on their disease stage and molecular profile, facilitating the selection of personalized treatment regimens, including targeted therapies and immunotherapies. The National Lung Screening Trial (NLST) demonstrated that low-dose CT screening could reduce lung cancer mortality by 20% compared to chest X-ray, highlighting the importance of early detection.

As diagnostic technologies continue to evolve, they contribute to more effective treatment decision-making, better patient outcomes, and improved survival rates, making them a key driver in the growth of the NSCLC market.

Shifting Demographics and Lifestyle Choices

The global population is aging, with a significant rise in the elderly demographic. As NSCLC is more prevalent among older individuals, this demographic shift has led to a higher incidence of the disease. Advances in healthcare have led to increased life expectancy. However, with age, the risk of NSCLC also rises. This demographic trend is driving the demand for both diagnostic and treatment services. While the prevalence of smoking has declined in some regions, it remains a major risk factor for NSCLC. The persistence of smoking habits among certain demographic groups continues to contribute to NSCLC incidence. Environmental factors, such as exposure to second-hand smoke and occupational hazards like asbestos, play a role in NSCLC development. Demographic groups with higher exposure to these factors face an increased risk.

Genetic predisposition to NSCLC can significantly influence its occurrence. Certain demographic groups may have a higher prevalence of genetic mutations that increase susceptibility to the disease. NSCLC risk can vary among different ethnicities due to genetic differences. Understanding these demographic variations is crucial for tailored prevention and treatment strategies.

Demographic disparities in healthcare access, often related to socio-economic factors, can impact early diagnosis and timely treatment initiation. Awareness of NSCLC risk factors and early symptoms can vary among different demographic groups. This influences the stage at which patients seek medical attention. Targeted interventions to promote smoking cessation, especially among high-risk demographic groups, can contribute to a reduction in NSCLC cases. Promoting healthy lifestyle choices, such as regular exercise and a balanced diet, can reduce NSCLC risk and improve overall health within specific demographics.

Key Market Challenges

Resistance to Treatment

Challenge: One of the foremost challenges in the NSCLC market is the development of resistance to treatment. NSCLC is known for its ability to adapt and evolve, often rendering initially effective therapies ineffective over time. This resistance can occur in response to chemotherapy, targeted therapies, and immunotherapies.

NSCLC tumors exhibit a high degree of heterogeneity, meaning that different regions of the tumor may have distinct genetic profiles. This heterogeneity can result in the survival of resistant cell populations. Genetic mutations within tumors can lead to the development of resistance mechanisms. For example, mutations in the EGFR gene can lead to resistance to EGFR inhibitors. The tumor microenvironment can foster drug resistance by creating conditions that protect cancer cells from treatment-induced damage.Identifying which patients will develop resistance and when it will occur remains a significant challenge. This hampers the ability to proactively manage resistance.

Resistance to treatment not only limits the effectiveness of existing therapies but also necessitates the development of new drugs and treatment strategies. This can increase the cost and complexity of NSCLC care and hinder overall market growth.

Key Market Trends

Precision Medicine and Targeted Therapies

Precision medicine and targeted therapies have emerged as pivotal trends in the treatment of Non-Small Cell Lung Cancer (NSCLC), revolutionizing the way this disease is managed. Advances in genomic profiling have enabled the identification of specific mutations, such as EGFR, ALK, ROS1, and BRAF, which are responsible for the growth and progression of NSCLC. By targeting these mutations directly, therapies can achieve higher efficacy and fewer side effects compared to conventional chemotherapy. These treatments are tailored to the genetic makeup of an individual's tumor, allowing for more personalized and effective care. The use of targeted therapies such as tyrosine kinase inhibitors (TKIs) has demonstrated improved progression-free survival rates and overall survival in patients with specific mutations.

The increasing use of next-generation sequencing (NGS) technologies is playing a crucial role in precision medicine by facilitating the detection of a wide range of genetic alterations in NSCLC. This technology enables healthcare providers to identify actionable biomarkers that guide treatment decisions, helping to optimize patient outcomes. For instance, the development of therapies like osimertinib for EGFR-mutant NSCLC and crizotinib for ALK-positive NSCLC has significantly advanced the treatment landscape, offering patients more effective and less toxic alternatives to traditional treatments.

The trend towards precision medicine is further fueled by the growing understanding of the tumor microenvironment and its role in tumor progression and resistance mechanisms. Researchers are now focused on identifying biomarkers that can predict not only response to therapies but also the potential for resistance, enabling more proactive and adaptive treatment strategies. As these targeted therapies continue to evolve, they are expected to dominate the NSCLC market, paving the way for more precise, personalized treatment regimens tailored to the unique genetic characteristics of each patient's cancer.

Segmental Insights

Type Insights

Based on the Type, Adenocarcinoma emerged as the dominant segment in the Global Non-Small Cell Lung Cancer Market in 2024. Non-Small Cell Lung Cancer, adenocarcinoma has emerged as the dominant player. Factors such as changing smoking patterns, environmental influences, advances in diagnostics, and the availability of targeted therapies have all contributed to its prominence within the global NSCLC market. As research continues to advance and our understanding of adenocarcinoma deepens, we can expect even more tailored and effective treatments for this prevalent subtype of lung cancer. Advancements in diagnostic techniques, particularly the widespread adoption of computed tomography (CT) scans and the development of molecular testing, have facilitated the early detection of adenocarcinoma. This early detection allows for more timely intervention and potentially better treatment outcomes. One of the most significant factors contributing to adenocarcinoma's dominance is the availability of targeted therapies. Adenocarcinoma is often associated with specific genetic mutations, such as EGFR and ALK. Targeted therapies that directly address these mutations have shown remarkable efficacy in treating adenocarcinoma patients, further solidifying its position in the NSCLC market. These factors are expected to drive the growth of this segment.

Key Market Players

  • Bayar Healthcare AG
  • Eli Lilly & Co.
  • Biogen Inc
  • Merck & Co
  • AbbVie Inc
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc
  • Avid Bioservices Inc
  • Blueprint Medicines Company

Report Scope:

In this report, the Global Non-Small Cell Lung Cancer Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Small Cell Lung Cancer Market, By Type:

  • Adenocarcinoma
  • Squamous Cell Carcinoma
  • Large Cell Carcinoma

Non-Small Cell Lung Cancer Market, By Treatment:

  • Chemotherapy
  • Immunotherapy
  • Radiation Therapy
  • Surgery
  • Targeted Therapy Drugs

Non-Small Cell Lung Cancer Market, By Drug Class:

  • Angiogenesis Inhibitor
  • Epidermal Growth Factor Receptor Blocker
  • Kinase Inhibitor
  • Microtubule Stabilizer
  • Folate Antimetabolites
  • PD-1/ PD-L1 Inhibitor

Non-Small Cell Lung Cancer Market, By End-User:

  • Hospitals & Clinics
  • Others

Non-Small Cell Lung Cancer Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Small Cell Lung Cancer Market.

Available Customizations:

Global Non-Small Cell Lung Cancer market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Drug Class
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Small Cell Lung Cancer Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma)
    • 5.2.2. By Treatment (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, Targeted Therapy Drugs)
    • 5.2.3. By Drug Class (Angiogenesis Inhibitor, Epidermal Growth Factor Receptor Blocker, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, PD-1/ PD-L1 Inhibitor)
    • 5.2.4. By End-User (Hospitals & Clinics, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2024)
  • 5.3. Market Map

6. North America Non-Small Cell Lung Cancer Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Treatment
    • 6.2.3. By Drug Class
    • 6.2.4. By End-User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Non-Small Cell Lung Cancer Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Treatment
        • 6.3.1.2.3. By Drug Class
        • 6.3.1.2.4. By End-User
    • 6.3.2. Canada Non-Small Cell Lung Cancer Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Treatment
        • 6.3.2.2.3. By Drug Class
        • 6.3.2.2.4. By End-User
    • 6.3.3. Mexico Non-Small Cell Lung Cancer Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Treatment
        • 6.3.3.2.3. By Drug Class
        • 6.3.3.2.4. By End-User

7. Europe Non-Small Cell Lung Cancer Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Treatment
    • 7.2.3. By Drug Class
    • 7.2.4. By End-User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Non-Small Cell Lung Cancer Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Treatment
        • 7.3.1.2.3. By Drug Class
        • 7.3.1.2.4. By End-User
    • 7.3.2. United Kingdom Non-Small Cell Lung Cancer Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Treatment
        • 7.3.2.2.3. By Drug Class
        • 7.3.2.2.4. By End-User
    • 7.3.3. Italy Non-Small Cell Lung Cancer Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Treatment
        • 7.3.3.2.3. By Drug Class
        • 7.3.3.2.4. By End-User
    • 7.3.4. France Non-Small Cell Lung Cancer Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Treatment
        • 7.3.4.2.3. By Drug Class
        • 7.3.4.2.4. By End-User
    • 7.3.5. Spain Non-Small Cell Lung Cancer Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Treatment
        • 7.3.5.2.3. By Drug Class
        • 7.3.5.2.4. By End-User

8. Asia-Pacific Non-Small Cell Lung Cancer Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Treatment
    • 8.2.3. By Drug Class
    • 8.2.4. By End-User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Non-Small Cell Lung Cancer Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Treatment
        • 8.3.1.2.3. By Drug Class
        • 8.3.1.2.4. By End-User
    • 8.3.2. India Non-Small Cell Lung Cancer Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Treatment
        • 8.3.2.2.3. By Drug Class
        • 8.3.2.2.4. By End-User
    • 8.3.3. Japan Non-Small Cell Lung Cancer Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Treatment
        • 8.3.3.2.3. By Drug Class
        • 8.3.3.2.4. By End-User
    • 8.3.4. South Korea Non-Small Cell Lung Cancer Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Treatment
        • 8.3.4.2.3. By Drug Class
        • 8.3.4.2.4. By End-User
    • 8.3.5. Australia Non-Small Cell Lung Cancer Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Treatment
        • 8.3.5.2.3. By Drug Class
        • 8.3.5.2.4. By End-User

9. South America Non-Small Cell Lung Cancer Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Treatment
    • 9.2.3. By Drug Class
    • 9.2.4. By End-User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Non-Small Cell Lung Cancer Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Treatment
        • 9.3.1.2.3. By Drug Class
        • 9.3.1.2.4. By End-User
    • 9.3.2. Argentina Non-Small Cell Lung Cancer Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Treatment
        • 9.3.2.2.3. By Drug Class
        • 9.3.2.2.4. By End-User
    • 9.3.3. Colombia Non-Small Cell Lung Cancer Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Treatment
        • 9.3.3.2.3. By Drug Class
        • 9.3.3.2.4. By End-User

10. Middle East and Africa Non-Small Cell Lung Cancer Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Treatment
    • 10.2.3. By Drug Class
    • 10.2.4. By End-User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Non-Small Cell Lung Cancer Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Treatment
        • 10.3.1.2.3. By Drug Class
        • 10.3.1.2.4. By End-User
    • 10.3.2. Saudi Arabia Non-Small Cell Lung Cancer Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Treatment
        • 10.3.2.2.3. By Drug Class
        • 10.3.2.2.4. By End-User
    • 10.3.3. UAE Non-Small Cell Lung Cancer Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Treatment
        • 10.3.3.2.3. By Drug Class
        • 10.3.3.2.4. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Non-Small Cell Lung Cancer Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Bayar Healthcare AG
  • 14.2. Eli Lilly & Co.
  • 14.3. Biogen Inc
  • 14.4. Merck $ Co
  • 14.5. AbbVie Inc
  • 14.6. AstraZeneca PLC
  • 14.7. Novartis AG
  • 14.8. Pfizer Inc
  • 14.9. Avid Bioservices Inc
  • 14.10.Blueprint Medicines Company

15. Strategic Recommendations

16. About Us & Disclaimer